【摘要】 目的：研究聚乙二醇干擾素α-2a注射液（派羅欣）聯(lián)合利巴韋林治療慢性丙肝臨床效果。方法：選擇筆者所在醫(yī)院2014年1月-2016年
　　6月診療的慢性丙肝患者55例，依據(jù)隨機分配的原理，將其中27例患者作為A組，實施利巴韋林聯(lián)合干擾素治療；28例患者作為B組，實施派羅欣聯(lián)合利巴韋林治療，對比分析兩組患者臨床療效與不良反應。結(jié)果：A組患者臨床總有效率為70.37%，B組患者臨床總有效率為96.43%，A組患者臨床總有效率低于B組患者，兩組患者臨床療效對比差異有統(tǒng)計學意義（P<0.05）。A組患者藥物不良反應為55.55%，B組患者藥物不良反應為32.14%，A組患者藥物不良反應雖高于B組患者，但差異無統(tǒng)計學意義（P>0.05）。結(jié)論：慢性丙肝臨床治療中，派羅欣聯(lián)合利巴韋林治療手段的運用，既可促進臨床療效的提升，又可降低患者藥物不良反應，值得推廣。
　　【關(guān)鍵詞】 派羅欣； 利巴韋林； 慢性丙肝
　　doi：10.14033/j.cnki.cfmr.2018.5.001 文獻標識碼 A 文章編號 1674-6805（2018）05-0001-03
　　【Abstract】 Objective：To study the curative effect of Pegasys united Ribavirin in the treatment of chronic hepatitis C.Method：fifty-five patients with chronic hepatitis c were selected from the hospital from January 2014 to June 2016.According to the principle of random assignment，27 patients were in group A，and the treatment of Interferon and Ribavirin were performed.The 28 patients were in group B，and the treatment of Pegasys combined with Ribavirin were performed，and the clinical efficacy and adverse reactions of the two groups were compared and analyzed.Result：The clinical total effective rate was 70.37% in group A patients，group B patients clinical total effective rate was 96.43%，group A of patients clinical total effective rate was lower than that of group B patients，there was statistically significant（P<0.05）.Group A of patients with adverse drug reactions was 55.55%，group B of patients with drug adverse reaction was 32.14%，the patients of group A was significantly higher than that of group B patients of adverse drug reactions，there was no statistical significance（P>0.05）.Conclusion：In the clinical treatment of chronic hepatitis C，the application of the combination of the treatment of Pegasys and Ribavirin can promote the improvement of clinical efficacy and reduce the adverse drug reaction of patients，which is worth promoting.
　　【Key words】 Pegasys； Ribavirin； Chronic hepatitis C
　　First-author’s address：The First People’s Hospital in Honghe Prefecture，Mengzi 661199，China
　　丙型病毒性肝炎（viral hepatitis type C，HC）即為丙型肝炎，因組織細胞遭受丙型肝炎病毒（HCV）侵蝕而誘發(fā)的疾病，主要以血源性傳播為主[1]。丙型肝炎沒有顯著的臨床癥狀和體征，疾病慢性化發(fā)展趨勢尤為嚴重，極易引起爆發(fā)性肝衰竭[2-3]。鑒于此，本研究選擇2014年1月-2016年6月診療的慢性丙肝患者55例為研究對象，研究聚乙二醇干擾素α-2a注射液（派羅欣）聯(lián)合利巴韋林治療慢性丙肝臨床效果，報道如下。
　　1 資料與方法
　　1.1 一般資料
　　選擇筆者所在醫(yī)院2014年1月-2016年6月診療的慢性丙肝患者55例，患者均經(jīng)病理檢查、臨床診斷確診為慢性丙肝，即ALT（丙氨酸氨基轉(zhuǎn)移酶）指標超過標準值1.5倍，總膽紅素低于17.0 mmol/L[4]。排除標準：妊娠期、哺乳期女性；短期內(nèi)給予抗病毒和免疫抑制治療患者；存在精神病史、自身免疫病史、失代償期肝硬化史患者。患者均知情同意本研究，本研究經(jīng)醫(yī)院倫理委員會批準。依據(jù)隨機分配的原則，將其中27例患者作為A組，28例患者作為B組。A組：男15例，女

相關(guān)熱詞搜索：丙肝 干擾素 注射液 臨床 效果